Pegvaliase
| Clinical data | |
|---|---|
| Trade names | Palynziq |
| Other names | Pegvaliase-pqpz; PEG-PAL; RAvPAL-PEG |
| Routes of administration | Subcutaneous injection |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Pegvaliase (trade name Palynziq) is a drug for the treatment of the genetic disease phenylketonuria. Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.[2]
It was approved by the Food and Drug Administration for use in the United States in May 2018.[3]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Palynziq". BioMarin Pharmaceutica.
- ^ "FDA approves a new treatment for PKU, a rare and serious genetic disease". Food and Drug Administration. May 24, 2018.